Revolution Medicines reports Phase 1/2 data for zoldonrasib combos in RAS G12D metastatic pancreatic cancer

Revolution Medicines

RVMD

0.00

Revolution Medicines released Phase 1/2 data for zoldonrasib combinations in RAS G12D metastatic pancreatic cancer at ESMO GI 2026.
First-line trial showed ORR 82% with modified FOLFIRINOX, ORR 61% with gemcitabine plus nab-paclitaxel.
Grade 3+ treatment-related adverse events were 61% with modified FOLFIRINOX, 80% with gemcitabine plus nab-paclitaxel; no Grade 5 events.
Previously treated cohort on zoldonrasib with daraxonrasib posted ORR 50% in second line, ORR 47% in third line-plus.
Data underpin Phase 3 strategy: ongoing RASolute 305; planned RASolute 309 in previously untreated RAS G12D metastatic PDAC.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Revolution Medicines Inc. published the original content used to generate this news brief on July 02, 2026, and is solely responsible for the information contained therein.

More This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.